News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests

 
• By Brian Bossetta, Reed Miller, Ashley Yeo, and Eliza Slawther

This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.

"News We're Watching" Feature Image
• Source: Medtech Insight

More from Regulation

More from Policy & Regulation